Prevention
What the evidence supports doing now.
COSMOS tested a daily multivitamin against placebo in more than 21,000 American seniors and found a small, repeatable slowing of cognitive aging. It is one of the only supplement results in dementia prevention that has held up, and it is smaller than the headlines suggest.
The CHOICE trial enrolled only older adults who already carried a diagnosis of mild cognitive impairment and hearing loss, the group a 2023 study had flagged as the one most likely to respond. Its main question came back negative. A second measure did not.
A pragmatic cluster-randomized trial tested a cheap nudge campaign in publicly funded senior centers, and measured something almost nobody measures: whether dementia prevention ever gets mentioned out loud.
A policy paper from the Global Brain Health Institute and Aga Khan University makes the case that poverty, wealth shocks, income inequality and HIV belong among the modifiable dementia risks, and that their absence tilts prevention toward risks more common in men.
A twin study scored every item on the 2024 Lancet Commission's prevention list against plasma Alzheimer's markers at once. In preliminary results, the whole list explained at most 8 percent of the variance, and none of the amyloid or pTau231 signal.
A cluster-randomized trial of nearly 34,000 rural Chinese adults found a 15 percent lower rate of dementia after seven years in villages where non-physician health workers managed blood pressure, extending earlier four-year findings from the same program.
A propensity-matched study of more than 21,000 Taiwanese adults with type 2 diabetes found GLP-1 receptor agonists nearly halved the risk of an overall dementia diagnosis compared with long-acting insulin, but the benefit vanished when Alzheimer's disease and vascular dementia were analyzed on their own.
Applying the 2024 Lancet Commission's 14-factor dementia checklist to a seven-decade Wisconsin cohort, researchers found the list works differently depending on a single gene: midlife diabetes tracked with dementia mainly in carriers of the APOE4 variant, while midlife hearing loss tracked with dementia mainly in people without it.
A new Lancet Public Health Viewpoint from Curtin University sorts every published modifiable dementia factor by where it actually operates. Four in five sit inside the individual. The authors say that says more about the research than about the risk.
The APPLE-Tree trial tested not what prevention advice should say but how it could reach people at scale. Its two-year cognition result missed statistical significance by a hair, and that is the honest headline.
A pooled analysis of 74 cohort studies found leisure-time exercise associated with lower dementia risk, while physical activity performed on the job was associated with higher risk, a split researchers say challenges blanket advice to "just be more active".
A single-blind randomized trial that followed 882 older adults in Italy for 48 months found higher Mini-Mental State Examination scores among cognitively healthy participants assigned to supervised exercise, but a smaller and statistically borderline effect in those with subjective memory complaints, and too few participants with mild cognitive impairment to draw conclusions.
A randomized trial of 513 older adults tested aerobic exercise, intensive blood pressure and cholesterol lowering, and the two combined against usual care. After two years, none of the four groups pulled ahead on a standard cognitive test.
A JAMA Neurology model put 1.8 percent of US dementia cases, more than 100,000 people, in the column marked vision impairment. A second, sharper measurement pushed the figure far higher. Neither study proves cause, and both changed the conversation about eye care.
A target-trial-emulation study of more than 500,000 Medicare beneficiaries found a 24 percent lower relative risk of dementia diagnosis over four years among those who received the recombinant shingles vaccine after a skilled-nursing-facility stay, extending earlier population-wide findings into a frailer group of older adults.
A four-year, 34,000-person trial using non-physician health workers to manage blood pressure in rural Chinese villages found significantly fewer dementia cases in intensively treated communities, among the most direct evidence yet linking blood pressure control to lower dementia incidence.
An American surgical society rewrote its thiamine advice in April 2025, raising the dose recommended before weight-loss surgery and before weight-loss medication. A year later, a review of Wernicke's cases in people taking semaglutide showed why that sentence mattered.
A PRISMA systematic review of 13 studies and 1,036 non-alcoholic patients reports Wernicke encephalopathy after bariatric, cancer and emergency gastrointestinal operations, with vomiting the commonest precipitating factor and confusion, ataxia and eye movement problems together in only a minority.
A Barcelona cohort dates the moment blood and spinal fluid tau in Down syndrome part company with everyone else's: about 37 years for plasma p-tau217. It is the most decision-relevant number in Down syndrome prevention, and it lands years before most trials open their doors.
A randomised trial in 81 adults, published online on 30 July, found small gains in processing speed and right hippocampal volume in the arm offered exercise three times a week, with no change in memory or executive function in any group.
An Amsterdam-led preprint finds polygenic scores for developmental dyslexia running high in semantic variant primary progressive aphasia, and only in the men. It is the first genetic hint behind the one risk factor PPA leaflets have always named, and it changes nothing anyone can do today.
An observational study of 58 people with semantic variant primary progressive aphasia found the cognitive reserve effect was confined to semantic tasks, and reversed over time
A 2025 meta-analysis pooled ten randomised trials of transcranial direct current stimulation in primary progressive aphasia. General naming and spelling improved. Everything else measured did not. Families asking about home devices deserve the pooled figure, not the best anecdote.
A Madrid trial gave 63 people with primary progressive aphasia half a year of theta-burst stimulation and word therapy. It is the longest sham-controlled test the syndrome has had. Its main result was a difference in brain metabolism so small the researchers themselves will not say what it means for a life.
A cross-sectional Canadian study of 25 serving operators found higher tau tracer uptake than in 10 lightly exposed military controls. A larger US study of blood markers alone found no rise with lifetime blast exposure. Neither is a diagnosis.
A CDC-commissioned workshop, published as a 146 page proceedings in April 2026, inventories practice contact limits, technique coaching, age rules and equipment, then marks, item by item, where the evidence stops.
Seven seasons of prospective injury surveillance by the IRFU and University of Limerick find sharp falls in tackle concussion among adult amateurs, and no such fall in schools, as World Rugby's lowered tackle height becomes global law
Analysis of 677 male donors to Boston University's UNITE Brain Bank found that a younger age of first tackle football exposure tracked with poorer family-reported cognition, behaviour and mood in those who died after 60, but not with more disease in the brain tissue itself.
A 296-person Harvard cohort wore pedometers for a week, then had their brains scanned for up to 14 years. The activity signal showed up in tau, not amyloid, and it flattened out around 5,000 to 7,500 steps a day.
For nearly fifty years, doctors have argued that putting thiamine in beer would prevent Korsakoff syndrome in the people least likely to ever ask for a prescription. Australia came closest, then put it in bread instead. A new peer-reviewed history asks what that swap actually bought.
A retrospective review of ten years of Veterans Affairs emergency records found no diagnoses of Wernicke's encephalopathy among 114 intoxicated patients given intravenous dextrose before thiamine, though the sample was small and the authors still back giving thiamine.
A genetic analysis in September said no amount of alcohol looks safe for the brain. A meta-analysis published on 10 December said the overall association is not significant. Both are peer reviewed. Here is what actually separates them.
The strategic plan published on 10 March 2026 commits to longer-term support in acute settings, a feasibility study on expanding specialist ARBD services, and an alcohol harm prevention action plan later this year.
A prospective study of 302 adult male amateur players in the Netherlands found small, temporary rises in p-tau217 and S100B after matches, with more headers and harder headers linked to larger changes. The markers returned to baseline within 24 to 48 hours.
In 1,865 dementia-free adults aged 60 and over in Stockholm, a diet with lower inflammatory potential was associated with lower dementia risk even among those with elevated blood p-tau217. The study was observational and cannot show that changing what you eat changes the disease.
DAN-ZOSTER, a nationwide pragmatic trial run through Danish health registries, is the first randomised test of the claim that the recombinant zoster vaccine lowers dementia risk. Results on dementia are not expected before 2029.
Pooled data from 61,089 hearing-impaired adults aged 55 and over across 33 countries found a 9 per cent lower rate of probable dementia among hearing aid users, but the association was confined to those who reported that their aid actually improved their hearing.
An emulated trial in more than 509,000 US Medicare beneficiaries with a recent skilled-nursing stay found a 5.8 percentage point lower four-year dementia risk among those given the recombinant zoster vaccine; the authors say residual confounding remains and call for a randomised trial.
The second edition of the World Health Organization's risk reduction guidelines, released on 15 July 2026, issues new recommendations on air pollution and on tailored multidomain programmes, and states that evidence was insufficient to recommend specific interventions for sleep, stroke, head injury, vision loss and HIV.